Related Experiment Video
Updated: Aug 18, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Cytochrome P-450 3A: interactions with dermatologic therapies
M I Singer1, L E Shapiro, N H Shear
1Division of Clinical Pharmacology, Sunnybrook Health Science Centre, Toronto, Ontario, Canada.
Abstract:
Recent case reports and studies suggest that interactions involving the cytochrome P-450 mixed function oxidase system are important causes of medication toxicity and decreased efficacy during combination drug therapy. The cytochrome P-450 3A3/4 isoenzyme is involved in many significant drug interactions. New and familiar drugs continue to be implicated as having potentially serious interactions with this group of enzymes. An understanding of the basic principles of these interactions may have a major impact on patient outcome.
Related Concept Videos
Pharmacokinetics: Drug–Drug Interactions
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Drug Toxicity: Allergic Reactions
Drug toxicity: Idiosyncratic Reactions
Drug toxicity: Drug–Drug Interaction

